Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CPIX POWR Grades
- CPIX scores best on the Value dimension, with a Value rank ahead of 97.95% of US stocks.
- CPIX's strongest trending metric is Sentiment; it's been moving up over the last 65 days.
- CPIX ranks lowest in Momentum; there it ranks in the 6th percentile.
CPIX Stock Summary
- CPIX has a higher market value than only 7.42% of US stocks; more precisely, its current market capitalization is $40,662,504.
- As for revenue growth, note that CPIX's revenue has grown -3.89% over the past 12 months; that beats the revenue growth of only 14.27% of US companies in our set.
- The volatility of Cumberland Pharmaceuticals Inc's share price is greater than that of 78.38% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Cumberland Pharmaceuticals Inc are MIND, CW, TBLT, OPK, and PLPC.
- CPIX's SEC filings can be seen here. And to visit Cumberland Pharmaceuticals Inc's official web site, go to www.cumberlandpharma.com.
CPIX Valuation Summary
- CPIX's price/earnings ratio is 1430; this is 3817.81% higher than that of the median Healthcare stock.
- CPIX's price/sales ratio has moved down 7.1 over the prior 147 months.
- Over the past 147 months, CPIX's price/earnings ratio has gone up 1369.7.
Below are key valuation metrics over time for CPIX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CPIX | 2021-08-31 | 1.1 | 0.9 | 1430.0 | 149.1 |
CPIX | 2021-08-30 | 1.1 | 0.9 | 1400.0 | 145.0 |
CPIX | 2021-08-27 | 1.1 | 0.9 | 1393.3 | 144.1 |
CPIX | 2021-08-26 | 1.1 | 0.9 | 1370.0 | 140.9 |
CPIX | 2021-08-25 | 1.0 | 0.8 | 1350.0 | 138.2 |
CPIX | 2021-08-24 | 1.1 | 0.9 | 1373.3 | 141.4 |
CPIX Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 45.75%.
- The year over year net income to common stockholders growth rate now stands at 53.16%.
- Its 3 year price growth rate is now at 22%.

The table below shows CPIX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 35.98504 | 6.342443 | -3.507587 |
2021-09-30 | 37.92672 | 5.236684 | -0.543665 |
2021-06-30 | 39.10486 | 6.19576 | 0.029876 |
2021-03-31 | 39.64756 | 6.312071 | -2.116959 |
2020-12-31 | 37.44113 | 5.415061 | -3.339408 |
2020-09-30 | 40.85797 | 5.41814 | -3.416338 |
CPIX Price Target
For more insight on analysts targets of CPIX, see our CPIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $8.50 | Average Broker Recommendation | 2 (Hold) |
CPIX Stock Price Chart Interactive Chart >
CPIX Price/Volume Stats
Current price | $2.04 | 52-week high | $7.51 |
Prev. close | $2.06 | 52-week low | $1.89 |
Day low | $2.02 | Volume | 1,800 |
Day high | $2.07 | Avg. volume | 68,845 |
50-day MA | $2.23 | Dividend yield | N/A |
200-day MA | $3.01 | Market Cap | 30.12M |
Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
Latest CPIX News From Around the Web
Below are the latest news stories about Cumberland Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPIX as an investment opportunity.
Cumberland Pharmaceuticals Inc. buys rights to oncology-related drug for $13.5 millionIn addition to the $13.5 million payment due at closing, Cumberland will pay Kyowa up to $3.5 million in milestones and tiered royalties of up to 10% on U.S. net sales. |
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICACumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company focused on discovering and delivering novel medicines. |
Cumberland Pharmaceuticals (NASDAQ:CPIX) Upgraded to C- by TheStreetTheStreet upgraded shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) from a d rating to a c- rating in a report published on Monday morning, TheStreetRatingsTable reports. Shares of NASDAQ:CPIX opened at $5.72 on Monday. Cumberland Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $7.51. The company has a debt-to-equity ratio of [] |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, traders! |
CPIX Price Returns
1-mo | N/A |
3-mo | -27.66% |
6-mo | -56.32% |
1-year | -29.90% |
3-year | -67.97% |
5-year | -70.86% |
YTD | -56.32% |
2021 | 58.31% |
2020 | -42.72% |
2019 | -14.59% |
2018 | -18.07% |
2017 | 33.82% |
Continue Researching CPIX
Here are a few links from around the web to help you further your research on Cumberland Pharmaceuticals Inc's stock as an investment opportunity:Cumberland Pharmaceuticals Inc (CPIX) Stock Price | Nasdaq
Cumberland Pharmaceuticals Inc (CPIX) Stock Quote, History and News - Yahoo Finance
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...